We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Molecular Pathway Traces Gene and Protein Activation in Breast Cancer

By LabMedica International staff writers
Posted on 17 Nov 2008
Cancer researchers have traced the molecular trail that links the ErbB2 (Her2/neu epidermal growth receptor family) oncogene to development of breast cancer via the activity of the Notch signaling pathway and its regulation of cyclin D1.

Approximately 25-30% of breast cancers have an amplification of the ErbB2 gene or overexpression of its protein product. More...
Overexpression of this receptor in breast cancer is associated with increased disease recurrence and worse prognosis. The associated Notch gene belongs to a family of epidermal growth factor (EGF) like genes, which encode transmembrane proteins with a variable number of cysteine-rich EGF-like repeats in the extracellular region. Four notch genes have been described in mammals, which have been implicated in the differentiation of the nervous system and other structures.

According to results published in the September 10, 2008, online edition of the journal Clinical and Translational Science cyclin D1 is the critical connection between ErbB2 and Notch. The cyclin D protein belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle. Mutations, amplification, and overexpression of this gene, which alters cell cycle progression, were observed frequently in a variety of tumors and might contribute to tumorigenesis.

Investigators at Thomas Jefferson University (Philadelphia, PA, USA) used two methods to suppress cyclin D1 expression in a laboratory mouse population. Either deletion of cyclin D1 was obtained by genetic engineering, or small interfering RNA (siRNA) was used to silence cyclin D1 expression. In either case, Notch signaling was reduced. Reintroduction of cyclin D1 into cyclin D1-deficient cells restored Notch1 activity through the inhibition of a protein called Numb, which is an endogenous inhibitor of Notch1 activity.

"Breast and other cancers are maintained through a population of cancer stem cells. By specifically targeting cancer stem cells we hope to reduce recurrence and improve therapy responses,” said senior author Dr. Richard Pestell, professor of cancer biology at Thomas Jefferson University.

Progressing towards that goal, this study has shown that cyclin D1 functions downstream as a genetic target of Notch1 and amplifies Notch1 activity by repressing Numb. This outlines a novel pathway by which ErbB2 induces Notch1 activity via the induction of cyclin D1.

Related Links:
Thomas Jefferson University


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.